Volume : 08, Issue : 10, October – 2021

Title:

27.SCREENING FOR PRIOR EXPOSURE TO HEPATITIS B VIRUS INFECTION IN PATIENTS UNDERGOING CHEMOTHERAPY

Authors :

Faisal Aslam, Mian Shah Yousaf, Yamna Jadoon, Samad Jehangir Shah, Arbab Muhammad Kashif Khan, Zaigham Abbas, Abdullah Bin Khalid

Abstract :

Introduction: Chemotherapy in patients with occult hepatitis can lead to the reactivation of Hepatitis B and even acute liver failure in immunosuppressed patients. We investigated the current trend of screening for previous exposure to hepatitis B in patients receiving chemotherapy in Pakistan.
Materials and Methods: In this retrospective multicenter study we collected data from the medical records of patients who underwent chemotherapy during a period of six months. Data were collected to assess the screening for Hepatitis before chemotherapy.
Results: A total of 182 patients who underwent chemotherapy were studied. The mean age of patients was 52.8 ± 14.9 years; 101(55.5%) were male. 140 (76.9%) were diagnosed with having solid organ malignancies while 42 (23.1%) were reported to have hematological malignancies. In our sample, 103 (56.6%) patients were screened for HBsAg, and amongst these patients, 3 patients tested positive. Hepatitis B core antibody (HBcAb) was checked in only 3 (1.6%) of the patients. The mean level of liver enzymes including ALT, AST, GGT, and ALP were 42.09, 38.98, 63.48 and 138.81, respectively. Ultrasound reports were available for 113 patients and the most common finding was a normal ultrasound 43(38.1%), followed by fatty liver 29 (25.7%).
Conclusion: Approximately half of the patients receiving chemotherapy are screened for active hepatitis B infection and screening for occult Hepatitis is almost negligible. Strategies are needed to ensure that all patients receiving chemotherapy should undergo complete screening of Hepatitis B before commencing chemotherapy.
Key Words: Occult hepatitis B, HBsAg, HBcAb, Immunosuppression, Chemotherapy.

Cite This Article:

Please cite this article in press Faisal Aslam et al, Screening For Prior Exposure To Hepatitis B Virus Infection In Patients Undergoing Chemotherapy., Indo Am. J. P. Sci, 2021; 08(10).

Number of Downloads : 10

References:

1. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005; 1:3-8. DOI:10.1055/s-2005-915644
2. Arababadi MK, Nasiri Ahmadabadi B, Yousefi Daredor H, et al. Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients. Hepat Mon. 2012; 12(5):315-9. doi: 10.5812/hepatmon.5934
3. Fang Y, Shang QL, Liu JY, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009; 58(5):383-8. DOI:10.1016/j.jinf.2009.02.013
4. Perrillo RP. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001; 120(4):1009-22. DOI:10.1053/gast.2001.22461
5. Cheng JC, Liu MC, Tsai SY, et al. Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer. 2004; 101(9):2126-33. DOI:10.1002/cncr.20591
6. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002; 99(7):2324-30. DOI:10.1182/blood.v99.7.2324
7. Meidani M, Rostami M, Hemmati S, et al. Screening and evaluation of chronic and occult Hepatitis B in chemoradiotherapy patients with cancer. Adv Biomed Res. 2016; 5(85):2277-9175. DOI:10.4103/2277-9175.182216
8. Herishanu Y, Katchman H, Polliack A. Severe hepatitis B virus reactivation related to ibrutinib monotherapy: Ann Hematol. 2017 Apr;96(4):689-690. DOI: 10.1007/s00277-016-2917-2. Epub 2017 Jan 5.
9. Gill H, Leung GMK, Seto WK, et al. Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment: Ann Hematol. 2019 Jan;98(1):215-218. DOI: 10.1007/s00277-018-3405-7. Epub 2018 Jun 26.
10. Guo L, Wang D, Ouyang X, et al. Recent Advances in HBV Reactivation Research. Biomed Res Int. 2018; 26(2931402). DOI:10.1155/2018/2931402
11. Elbedewy TA, Elashtokhy HE, Rabee ES, et al. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen-negative patients with diffuse large B-cell lymphoma: the significance of hepatitis B core antibodies screening. J Egypt Natl Canc Inst. 2015; 27(1):11-8. DOI:10.1016/j.jnci.2015.01.004
12. Said ZNA. An overview of occult hepatitis B virus infection. World journal of gastroenterology. 2011; 17(15):1927-38. DOI:10.3748/wjg.v17.i15.1927 doi: 10.3748/wjg.v17.i15.1927
13. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67(4):1560-99. DOI:10.1002/hep.29800
14. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology international. 2015; 10(1):1-98. DOI:10.1007/s12072-015-9675-4 DOI:10.1007/s12072-015-9675-4
15. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370-98. DOI:10.1016/j.jhep.2017.03.021
16. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology. 2015; 148(1):221-44.e3. DOI:10.1053/j.gastro.2014.10.038 DOI:10.1053/j.gastro.2014.10.038
17. Cholongitas E, Tziomalos K, Pipili C. Management of patients with hepatitis B in special populations. World J Gastroenterol. 2015; 21(6):1738-48. DOI:10.3748/wjg.v21.i6.1738
18. Vigano M, Serra G, Casella G, et al. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opin Biol Ther. 2016; 16(7):917-26. DOI:10.1080/14712598.2016.1177017
19. Phipps C, Chen Y, Tan D. Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy. Clinical Lymphoma, Myeloma, and Leukemia. 2016; 16(1):5-11. DOI:10.1016/j.clml.2015.11.009
20. Voican CS, Mir O, Loulergue P, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol. 2016; 27(12):2172-84. DOI:10.1093/annonc/mdw414
21. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013; 31(22):2765-72. DOI:10.1200/JCO.2012.48.5938
22. Buti M, Manzano ML, Morillas RM, et al. Prevents HBV Reactivation with Tenofovir in Anti-HBC Positive Patients with Hematologic Malignancies Treated with Rituximab. Results Final Visit 18-Months (Preblin Study). Journal of Hepatology. 2016; 64(2):S369. DOI:10.1016/s0168-8278(16)00552-3 DOI:10.1371/journal.pone.0184550
23. Ali M, Idrees M, Ali L, et al. Hepatitis B virus in Pakistan: a systematic review of prevalence, risk factors, awareness status, and genotypes. Virology journal. 2011; 8:102-. DOI:10.1186/1743-422X-8-102